Literature DB >> 1904324

Disodium cromoglycate (DSCG) selectively inhibits IgE production and enhances IgG4 production by human B cell in vitro.

H Kimata1, A Yoshida, C Ishioka, H Mikawa.   

Abstract

The effect of DSCG on human IgE production in vitro was studied. DSCG selectively inhibited interleukin-4 (IL-4) induced IgE production by mononuclear cells (MNC) from normal donors without affecting IgM, IgA, IgG1, IgG2 or IgG3 production. In contrast, DSCG enhanced IgG4 production. To achieve this effect, DSCG must be added to the culture at the initiation and be present throughout the entire culture period. Interferon-gamma (IFN-gamma) also inhibited IL-4-induced IgE production, but IgG4 production was not affected by IFN-gamma. Monoclonal anti-IFN-gamma antibody blocked the inhibition of IgE production by IFN-gamma, but did not block the inhibition of IgE production by DSCG. DSCG also selectively inhibited spontaneous IgE production and enhanced IgG4 production by B cells from atopic patients in the presence of T cells and monocytes. These results indicate that there is a mechanism of IgE production inhibition which is not mediated by IFN-gamma. We also found that DSCG is an excellent reagent for the study of IgE and IgG4 regulation in vitro.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1904324      PMCID: PMC1535423     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  22 in total

1.  Role for T cells, IL-2 and IL-6 in the IL-4-dependent in vitro human IgE synthesis.

Authors:  E Maggi; G F Del Prete; P Parronchi; A Tiri; D Macchia; P Biswas; C Simonelli; M Ricci; S Romagnani
Journal:  Immunology       Date:  1989-11       Impact factor: 7.397

2.  Subset of natural killer cells is induced by immune complexes to display Fc receptors for IgE and IgA and demonstrates isotype regulatory function.

Authors:  H Kimata; A Saxon
Journal:  J Clin Invest       Date:  1988-07       Impact factor: 14.808

3.  Disodium cromoglycate inhibits activation of human inflammatory cells in vitro.

Authors:  A B Kay; G M Walsh; R Moqbel; A J MacDonald; T Nagakura; M P Carroll; H B Richerson
Journal:  J Allergy Clin Immunol       Date:  1987-07       Impact factor: 10.793

4.  Evaluation of production and characterization of monoclonal antibodies to human IgG of four subclasses.

Authors:  S Harada; S Nishimura; A Saiga; S Hosoi; H Mikawa
Journal:  Microbiol Immunol       Date:  1989       Impact factor: 1.955

5.  Honey bee venom specific immunoglobulin G4 in honey bee sting allergic patients and bee keepers.

Authors:  N K Cheung; J Blessing-Moore; M J Reid; G Yang
Journal:  Ann Allergy       Date:  1983-03

6.  Effect of recombinant human interleukin 4 on spontaneous in vitro human IgE synthesis.

Authors:  X D Yang; A L De Weck; B M Stadler
Journal:  Eur J Immunol       Date:  1988-11       Impact factor: 5.532

7.  Modulation of IL-4-induced human IgE production in vitro by IFN-gamma and IL-5: the role of soluble CD23 (s-CD23).

Authors:  J Pène; I Chrétien; F Rousset; F Brière; J Y Bonnefoy; J E de Vries
Journal:  J Cell Biochem       Date:  1989-03       Impact factor: 4.429

8.  Nerve growth factor specifically induces human IgG4 production.

Authors:  H Kimata; A Yoshida; C Ishioka; T Kusunoki; S Hosoi; H Mikawa
Journal:  Eur J Immunol       Date:  1991-01       Impact factor: 5.532

9.  T cell clones providing helper function for IgE synthesis release soluble factor(s) that induce IgE production in human B cells: possible role for interleukin 4 (IL-4).

Authors:  E Maggi; G F Del Prete; A Tiri; D Macchia; P Parronchi; M Ricci; S Romagnani
Journal:  Clin Exp Immunol       Date:  1988-07       Impact factor: 4.330

10.  IgE production by normal human lymphocytes is induced by interleukin 4 and suppressed by interferons gamma and alpha and prostaglandin E2.

Authors:  J Pène; F Rousset; F Brière; I Chrétien; J Y Bonnefoy; H Spits; T Yokota; N Arai; K Arai; J Banchereau
Journal:  Proc Natl Acad Sci U S A       Date:  1988-09       Impact factor: 11.205

View more
  11 in total

Review 1.  Prospects for preventing asthma.

Authors:  P J Helms; G Christie
Journal:  Arch Dis Child       Date:  1999-05       Impact factor: 3.791

2.  Glutaric aciduria and suspected child abuse.

Authors:  A A Morris; G F Hoffmann; E R Naughten; A A Monavari; J E Collins; J V Leonard
Journal:  Arch Dis Child       Date:  1999-05       Impact factor: 3.791

Review 3.  Clinical pharmacology of asthma. Implications for treatment.

Authors:  A J Frew; S T Holgate
Journal:  Drugs       Date:  1993-11       Impact factor: 9.546

4.  Interleukin-12 suppresses immunoglobulin E production but enhances immunoglobulin G4 production by human peripheral blood mononuclear cells.

Authors:  B A de Boer; Y C Kruize; P J Rotmans; M Yazdanbakhsh
Journal:  Infect Immun       Date:  1997-03       Impact factor: 3.441

Review 5.  Corticosteroid-sparing options in the treatment of childhood asthma.

Authors:  P J Helms
Journal:  Drugs       Date:  2000       Impact factor: 9.546

Review 6.  Anti-inflammatory agents in allergic diseases.

Authors:  C A Bonham; A W Thomson
Journal:  Clin Exp Immunol       Date:  1995-10       Impact factor: 4.330

Review 7.  Ocular allergy guidelines: a practical treatment algorithm.

Authors:  Leonard Bielory
Journal:  Drugs       Date:  2002       Impact factor: 9.546

8.  Differential antibody isotype reactivity to specific antigens in human lymphatic filariasis: gp15/400 preferentially induces immunoglobulin E (IgE), IgG4, and IgG2.

Authors:  M Yazdanbakhsh; W A Paxton; A Brandenburg; R Van Ree; M Lens; F Partono; R M Maizels; M E Selkirk
Journal:  Infect Immun       Date:  1995-10       Impact factor: 3.441

9.  Effect of topical cromoglycate solution on atopic dermatitis: combined treatment of sodium cromoglycate solution with the oral anti-allergic medication, oxatomide.

Authors:  H Kimata; S Hiratsuka
Journal:  Eur J Pediatr       Date:  1994-02       Impact factor: 3.183

10.  Interleukin 8 (IL-8) selectively inhibits immunoglobulin E production induced by IL-4 in human B cells.

Authors:  H Kimata; A Yoshida; C Ishioka; I Lindley; H Mikawa
Journal:  J Exp Med       Date:  1992-10-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.